Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company’s ...

晒单时间到！分享我在#2024美股模拟交易9月月赛#委托交易的$NuCana NCNA$ ...

Instil Bio, Inc. TIL shares dropped 25% to $63.50. The company announced the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in ...

NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...

US equity futures were mixed before the opening bell on Monday as traders awaited the Federal Reserve's regular meeting to discuss monetary policy. Dow Jones Industrial Average futures gained 0.2%, ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00.

Shares of Exicure, Inc. (NASDAQ:XCUR) rose sharply in today's pre-market trading after the company entered into ...

NuCana plc is a clinical-stage biopharmaceutical company dedicated to enhancing cancer treatments through its ProTide technology. This innovative approach transforms conventional chemotherapy agents, ...

NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98. However ...

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 ...